Research
Micronutrients & recovery
Inhibition of Stearoyl-CoA desaturase 1 (SCD1) protects against hepatic steatosis (fatty liver) by decreasing de novo fatty acid synthesis and increasing fatty acid oxidation.
Fatty liver disease is closely linked to the activity of the SCD1 enzyme. Research in mice shows that inhibiting this enzyme reduces liver fat by shifting metabolism toward fat burning and away from fat storage. This suggests that therapies targeting SCD1 could help treat non-alcoholic fatty liver disease.
ModerateSupportsMEDIUM confidence
Much evidence points to a direct anti-steatotic effect of SCD1 deficiency on liver to reduce lipid content by enhancing oxidation and blocking lipogenesis.
Why this rating
Based on murine models showing reduced liver triglycerides and cholesterol esters.
Source
Stearoyl‐CoA desaturase as a new drug target for obesity treatment
Agnieszka Dobrzyń et al. · Obesity Reviews · 2005
narrative_reviewCited 173×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →